Corvus Pharmaceuticals (CRVS) Consolidated Net Income (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Consolidated Net Income of -$13.1 million for Q1 2026, down 183.23% year-over-year from $15.7 million in Q1 2025, and down 33.14% quarter-over-quarter from -$9.8 million in Q3 2025.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Consolidated Net Income (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Consolidated Net Income history runs 12 years deep, the most recent figure standing at -$13.1 million for Q1 2026.
- In Q1 2026, Consolidated Net Income fell 183.23% year-over-year to -$13.1 million; the TTM figure through Mar 2026 stood at -$30.5 million (down 11.09% YoY), while the FY2025 annual figure was -$102.1 million, down 12.78% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$13.1 million, down from -$9.8 million in the prior quarter.
- The five-year high for Consolidated Net Income was $15.7 million in Q1 2025, with the low at -$39.5 million in Q3 2024.
- The 5-year median for Consolidated Net Income is -$6.1 million (2023), against an average of -$8.0 million.
- The sharpest annual moves came in 2024 and 2025: Consolidated Net Income tumbled 669.91% in 2024, then jumped 364.98% in 2025.
- Corvus Pharmaceuticals' Consolidated Net Income stood at -$5.8 million in 2022, then gained by 0.8% to -$5.7 million in 2023, then plunged by 589.72% to -$39.5 million in 2024, then surged by 75.13% to -$9.8 million in 2025, then plunged by 33.14% to -$13.1 million in 2026.
- Business Quant data shows CRVS's Consolidated Net Income at -$13.1 million in Q1 2026, -$9.8 million in Q3 2025, and -$7.6 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Corvus Pharmaceuticals | 1.34 Bn | 1.12 Bn | - | -17.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.25 Mn |
| Mar 31, 2026 | -13.09 Mn |
| Sep 30, 2025 | -9.83 Mn |
| Jun 30, 2025 | -7.61 Mn |
| Mar 31, 2025 | 15.73 Mn |
| Sep 30, 2024 | -39.54 Mn |
| Jun 30, 2024 | -3.69 Mn |
| Mar 31, 2024 | -5.94 Mn |
| Dec 31, 2023 | -5.27 Mn |
| Sep 30, 2023 | -5.14 Mn |
| Jun 30, 2023 | -5.22 Mn |
| Mar 31, 2023 | -6.14 Mn |
| Dec 31, 2022 | -5.35 Mn |
| Sep 30, 2022 | -12.25 Mn |
| Jun 30, 2022 | -6.91 Mn |
| Mar 31, 2022 | -7.40 Mn |
| Dec 31, 2021 | -6.82 Mn |
| Sep 30, 2021 | -9.06 Mn |
| Jun 30, 2021 | -11.29 Mn |
| Mar 31, 2021 | -11.48 Mn |